Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
(NASDAQ:SGMO) SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM 2025
Related Questions
How will the detailed STAAR study results affect Sangamo's upcoming regulatory filings and potential FDA approval timeline?
What efficacy and safety data were presented, and how do they compare to existing therapies for Fabry disease?
What is the expected market size and revenue impact for Sangamo if the therapy progresses toward commercialization?